Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib

被引：0
|
作者：
Goldenberg, D. M. [1 ]
Cardillo, T. M. [1 ]
Govindan, S. V. [1 ]
Zalath, M. [1 ]
Arrojo, R. [1 ]
Sharkey, R. M. [1 ]
机构：
[1] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-02
引用
收藏
页数：2
相关论文
共 36 条
  • [31] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
    Starodub, Alexander
    Ocean, Allyson J.
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Salim Samuel
    Messersmith, Wells A.
    Shah, Manlsh A.
    Vandat, Linda T.
    Chuang, Ellen
    Lin, Bruce S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Vahdat, Linda T.
    Chuang, Ellen
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [33] COMBINED PARENT AND PAYLOAD POPULATION PHARMACOKINETIC MODELING TO SUPPORT DOSE RECOMMENDATION OF THE NOVEL ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE (ADC) SHR-A1921
    Wang, J.
    Rao, J.
    Li, S.
    Shen, K.
    Lin, Z.
    Zhang, Z.
    Wang, S.
    Wang, Q.
    Djebli, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S83 - S83
  • [34] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [35] Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2-metastatic breast cancer (mBC)
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Vahdat, Linda T.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Juric, Dejan
    Sharkey, Robert M.
    Washkowitz, Sarah A.
    Wegener, William A.
    Goldenberg, David M.
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
    Kalinsky, K.
    Isakoff, S. J.
    Tolaney, S. M.
    Juric, D.
    Mayer, I. A.
    Vahdat, L. T.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Shah, N. C.
    Abramson, V.
    Goldenberg, D. M.
    Sharkey, R. M.
    Washkowitz, S. A.
    Wegener, W. A.
    Iannone, R.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
1234